Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.55 |
| ▸ | CCND1 | P24385 | 4/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342105 | 0.92 | CDK4 (0.53) | CDK4CCND1ABCB1HTR4DRD2 | |
| SCHEMBL5336162 | 0.88 | ABCB1 (0.53) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5334617 | 0.86 | ABCB1 (0.51) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5345692 | 0.86 | CDK4 (0.59) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5333509 | 0.85 | CDK4 (0.58) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5332190 | 0.84 | CDK4 (0.56) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5332158 | 0.83 | CDK4 (0.63) | CDK4CCND1ABCB1SIGMAR1DRD2 | |
| SCHEMBL5338969 | 0.82 | CDK4 (0.55) | CDK4CCND1ABCB1SIGMAR1HTR4 | |
| SCHEMBL5339628 | 0.80 | CDK4 (0.50) | CDK4CCND1ABCB1DRD2P2RX7 | |
| SCHEMBL5345261 | 0.80 | CDK4 (0.55) | CDK4CCND1ABCB1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CDK4 2839/4885CCND1 3348/4885ABCB1 3447/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | CDK4 2839/4885CCND1 3348/4885ABCB1 3447/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CDK4 2839/4885CCND1 3348/4885ABCB1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.